Our data suggest that phosphatidylcholine levels in the liver are lower in early metabolic dysfunction–associated steatohepatitis in mice and that supplementation of phosphatidylcholine can diminish the development of metabolic dysfunction–associated steatotic liver disease through mechanisms involving LRH-1/PPARγ2/ nuclear factor κ-light-chain enhancer of activated B-cell signaling. This evidence concerns the gene NR5A2 and liver disorder.